Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 9 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma ESMO Calls for Cancer to Remain a Flagship Priority in the Next EU Budget MOST POPULAR Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A July 20, 2023 17 Old Fashioned Ways to Get Rid of Ants in Your... March 27, 2019 Pruebas genéticas para el cáncer en familias: Preguntas y respuestas con... May 19, 2022 Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the... July 11, 2022 Load more HOT NEWS Running a cancer helpline in COVID-19: two years on the virtual... Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia New hormone treatment for advanced prostate cancer made available in England Philanthropist Simon Collins: “I realised I could make a difference by...
